Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity
Go back to Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity| Lilly (Eli) & Co. (NYSE: LLY) | Delayed: 1123.91 -25.45 (2.21%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1149.36 | 52 Week High | $88.16 | |||
| Open | $1133.00 | 52 Week Low | $67.88 | |||
| Day High | $1134.53 | P/E | 260.16 | |||
| Day Low | $1113.55 | EPS | $4.32 | |||
| Volume | 2,401,650 | |||||
